Joshua Meier, CEO of biotechnology company Provita Pharmaceuticals, spends about 20 hours a week on research projects in the various labs at his disposal. In January, the company gave a presentation to the FDA on its work with the flying syringe, a tool that uses mosquitoes as a vector to deliver vaccines to those who need them. Provita has also submitted a grant idea to the Bill and Melinda Gates Foundation. But you might not recognize Meier as a CEO if you saw him walking down the street–he’s 16. In fact, everyone on the 15-plus person Provita team, from research and development workers to finance officers, is in high school.
Provita was founded in 2008, before Meier–a junior and a finalist in the 2012 Google Science Fair–entered high school at the Bergen County Academies, a group of seven magnet high school programs that each hone in on different subjects, including a program focused on science and technology (where Meier is a student), a business and finance program, and a medical science and technology program. Provita emerged when some of the science-focused kids decided to collaborate with the business-minded students on a business plan competition for their research.
The company’s first product, Coagula, aims to decrease the number of injections that patients with hemophilia and von Willebrand disease have to endure. “Hemopheliacs have uncontrolled bleeding, and they to have to take coagulants to make their blood thicker. The problem with treatment is that they have to take it several time a week, and there are issues of infection and having transfusions all the time,” explains Meier. “We came up with new method, so instead of taking treatment a few times a week, you do it once every few months. We’re still working on that.”
The Provita team certainly has enough equipment at its disposal, including a stem cell lab and a microbiology lab that the school provides for all students. All of the company’s work is funded by the Bergen County Technical Schools district (the district also funds other student research projects). Memorial Sloan Kettering Cancer Center in New York City has even indicated interest in helping with future development.
More recently, Provita has started working on the flying syringe. That project is still in the very early stages. “We can’t really culture mosquitoes in the lab at our high school because that’s dangerous, but we a have research advisor and ideas planned out, and the next step is making a partnership, contacting other places that do have animal facilities,” says Meier.
The first goal: to genetically engineer mosquitoes so that they can produce and deliver a vaccine (via their saliva) for West Nile Virus. The mosquitoes, Meier explains, will be sterilized to prevent any out-of-control problems. It’s a new twist on research being done elsewhere to breed sterile mosquitoes in malaria-infested areas.
Meier hopes to keep up with Provita’s research after he graduates, but “most of the hard work will stay in the high school,” he says. That’s partially because the school has some control of Provita’s intellectual property since much of it was developed on campus (one huge benefit of that: the school district pays for all of Provita’s research).
In any case, says Meier, “it’s not like we’re out here to get a profit. We’re doing this because most of us want to start our own companies or go into research. We’re here as an educational experience.”